Natco Pharma Launches Affordable Semaglutide Generic In India

Natco Pharma’s latest launch marks a significant milestone in India’s pharmaceutical landscape, bringing a cost-effective alternative to semaglutide injections. With rising demand for diabetes and weight management therapies, the company’s pricing strategy is expected to make advanced treatment more accessible to patients.

Product Details
The multi-dose vials have already been introduced in the market, while pen devices are scheduled for release in April 2026. By offering tiered pricing, Natco Pharma seeks to cater to diverse patient needs and affordability levels. Analysts believe this launch could disrupt the market by challenging high-cost branded options.

Market Impact
The introduction of semaglutide generics is expected to boost competition in India’s diabetes care segment. With affordability as a key driver, Natco Pharma’s move may accelerate adoption among patients and strengthen its position in the domestic pharmaceutical market.

Key Highlights

• Natco Pharma launches semaglutide generic multi-dose vials
• Prices set at ₹1,290 and ₹1,750 per month
• Pen devices priced at ₹4,000 and ₹4,500 per month, launch in April 2026
• Focus on diabetes and obesity treatment accessibility
• Analysts expect strong market disruption and adoption

Sources: Economic Times, Business Standard, Reuters